G
Gad Getz
Researcher at Broad Institute
Publications - 627
Citations - 309042
Gad Getz is an academic researcher from Broad Institute. The author has contributed to research in topics: Cancer & Biology. The author has an hindex of 189, co-authored 520 publications receiving 247560 citations. Previous affiliations of Gad Getz include University of Colorado Denver & University of California, San Diego.
Papers
More filters
Journal ArticleDOI
Systematic Identification of Personal Mutated Tumor-Specific Neoantigens in CLL
Mohini Rajasagi,Derin B. Keskin,Jintaek Kim,Wandi Zhang,Sachet A. Shukla,David S. DeLuca,John Sidney,Vladimir Brusic,Donna Neuberg,Gad Getz,Eric S. Lander,Nir Hacohen,Catherine J. Wu +12 more
TL;DR: Results from next-generation DNA sequencing are exploited to detect somatic mutations together with algorithms that predict peptide binding to HLA class I and to determine if tumor neoantigens are naturally recognized by cytotoxic T lymphocytes.
Posted ContentDOI
Origins of cancer genome complexity revealed by haplotype-resolved genomic analysis of evolution of Barretts esophagus to esophageal adenocarcinoma
Casey H Zhang,Stachler M,Chunyang Bao,Chunyang Bao,Richard W. Tourdot,Richard W. Tourdot,Gregory J. Brunette,Chip Stewart,Lili Sun,Lili Sun,Hideo Baba,Masayuki Watanabe,Agoston T. Agoston,Kunal Jajoo,Katie S. Nason,Jon M. Davison,Gad Getz,Kenneth K. Wang,Yu Imamura,Robert D. Odze,Adam J. Bass,Adam J. Bass,Adam J. Bass +22 more
TL;DR: In this paper, the authors studied the evolution dynamics of chromosomal copy-number evolution in the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) by multi-regional whole-genome sequencing analysis.
Journal ArticleDOI
Analyzing Frequently Mutated Genes and the Association With Tumor Mutation Load.
Posted ContentDOI
Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer
Alok K. Tewari,Alok K. Tewari,Alexander T. M. Cheung,Alexander T. M. Cheung,Jett Crowdis,Jett Crowdis,Jake Conway,Jake Conway,Sabrina Y. Camp,Sabrina Y. Camp,Stephanie A. Wankowicz,Stephanie A. Wankowicz,Dimitri Livitz,Jihye Park,Jihye Park,Rosina T. Lis,Alice Boosma-Moody,Alice Boosma-Moody,Meng Xiao He,Meng Xiao He,Saud H. AlDubayan,Saud H. AlDubayan,Saud H. AlDubayan,Zhenwei Zhang,Rana R. McKay,Ignaty Leshchiner,Myles Brown,Steve Balk,Gad Getz,Gad Getz,Mary-Ellen Taplin,Eliezer M. Van Allen,Eliezer M. Van Allen +32 more
TL;DR: In this paper, the authors performed whole exome (WES) and whole transcriptome sequencing (RNA-seq) on pre-treatment multi-regional tumor biopsies from exceptional responders (ER: pCR and MRD patients) and non-responders (NR: pathologic T3 or lymph node positive disease) treated with intensive anti-androgen therapies prior to prostatectomy.
Proceedings ArticleDOI
Abstract 4114: Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in FGFR2 fusion-positive cholangiocarcinoma patients
Lipika Goyal,Supriya K. Saha,Leah Y. Liu,Giulia Siravegna,Ignaty Leshchiner,Leanne G. Ahronian,Jochen K. Lennerz,Phuong Vu,Benedetta Mussolin,Stephanie Reyes,Pascal Furet,A. John Iafrate,Gad Getz,Diana Graus Porta,Ralph Tiedt,Alberto Bardelli,Dejan Juric,Ryan B. Corcoran,Nabeel Bardeesy,Andrew X. Zhu +19 more
TL;DR: This report provides the first genetic evidence of clinical acquired resistance to FGFR inhibitor therapy in patients and informs future strategies for detecting mechanisms of resistance and promoting more durable remissions.